AK Medical Holdings (HKG:1789) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Jumps 20% This Past Week
AK Medical Holdings (HKG:1789) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Jumps 20% This Past Week
AK Medical Holdings Limited (HKG:1789) shareholders should be happy to see the share price up 20% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years. After all, the share price is down 49% in the last three years, significantly under-performing the market.
爱康医疗控股有限公司(HKG:1789)的股东应该很高兴看到股价在上个月上涨了20%。 但这并不能掩盖过去三年收益不佳的事实。毕竟,股价在过去三年下跌了49%,明显表现不佳。
Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline.
尽管过去一周对股东来说更令人放心,但在过去的三年中,他们仍然处于亏损状态,因此让我们看看基本业务是否对下降负责。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
虽然一些人仍然相信有效市场假说,但已经证明市场是过度反应的动态系统,投资者并不总是理性的。一个不完美但简单的方法来考虑公司市场看法的变化是比较每股收益(EPS)的变化和股价的波动。
AK Medical Holdings saw its EPS decline at a compound rate of 11% per year, over the last three years. This reduction in EPS is slower than the 20% annual reduction in the share price. So it seems the market was too confident about the business, in the past.
爱康医疗控股在过去三年以每年11%的复合率下降了EPS。 EPS的减少速度低于股价每年下降20%的速度。因此,市场似乎过去对该业务过于自信。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下图显示了EPS随时间的变化情况(如果您单击该图像,则可以查看更多详细信息)。
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..
我们很高兴地报告,该公司CEO的薪酬比同等资本化公司的大多数CEO都要适度。关注CEO的薪酬很重要,但更重要的问题是公司能否在未来年份中增长收益。在买入或卖出股票之前,我们始终建议仔细审查历史增长趋势,此处提供历史增长趋势。
A Different Perspective
不同的观点
While the broader market gained around 22% in the last year, AK Medical Holdings shareholders lost 13% (even including dividends). However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 5% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. Before forming an opinion on AK Medical Holdings you might want to consider these 3 valuation metrics.
尽管整体市场在过去一年中上涨了约22%,但爱康医疗控股股东损失了13%(即使包括分红派息)。然而,请记住,即使最好的股票有时也会在十二个月的时间内表现不佳。不幸的是,去年的表现可能表明存在未解决的挑战,因为表现比过去半个世纪的年化损失5%还要糟糕。我们意识到巴伦·罗斯柴尔德曾说过投资者应该在"街上流血时买进",但我们提醒投资者首先要确信他们在购买高质量的业务。在对爱康医疗控股形成观点之前,您可能需要考虑这3个估值指标。
But note: AK Medical Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但请注意:爱康医疗控股可能不是最佳的股票选择。因此,请查看这份免费的有过去收益增长(和进一步增长预测)的有趣公司名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.
请注意,本文引用的市场回报反映了当前在香港证券交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。